Company Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.
The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004.
Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Chaim Lebovits |
Contact Details
Address: 1325 Avenue Of Americas, 28th Floor New York, New York 10019 United States | |
| Phone | 201-488-0460 |
| Website | brainstorm-cell.com |
Stock Details
| Ticker Symbol | BCLI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001137883 |
| CUSIP Number | 10501E201 |
| ISIN Number | US10501E2019 |
| Employer ID | 20-7273918 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chaim Lebovits | President and Co-Chief Executive Officer |
| Dr. Stacy R. Lindborg Ph.D. | Co-Chief Executive Officer |
| Dr. Irit Arbel DSc, Ph.D. | Co-Founder and Independent Vice Chair of the Board |
| Alla Patlis CPA, M.B.A. | Interim Chief Financial Officer and Controller |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary and Director |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor |
| Mary Kay Turner | Senior Vice President of Patient Advocacy and Government Affairs |
| Dr. Ibrahim Dagher M.D. | Executive Vice President and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 20, 2023 | 8-K | Current Report |
| Nov 22, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |